Back to Search
Start Over
COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions
- Source :
- mSphere, Vol 5, Iss 3 (2020), mSphere, mSphere, Vol 5, Iss 3, p e00317-20 (2020)
- Publication Year :
- 2020
- Publisher :
- American Society for Microbiology, 2020.
-
Abstract
- Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first emerged in December 2019 in Wuhan, Hubei province, China. Since then, the virus has rapidly spread to many countries. While the outbreak in China appears to be in decline, the disease has spread across the world, with a daily increase in the number of confirmed cases and infection-related deaths. Here, we highlight (i) the lessons that have been learnt so far and how they will benefit reducing the impact of COVID-19 disease and (ii) an update on the status of drug treatment and vaccine development to prevent COVID-19 and potential future related pandemics.<br />Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first emerged in December 2019 in Wuhan, Hubei province, China. Since then, the virus has rapidly spread to many countries. While the outbreak in China appears to be in decline, the disease has spread across the world, with a daily increase in the number of confirmed cases and infection-related deaths. Here, we highlight (i) the lessons that have been learnt so far and how they will benefit reducing the impact of COVID-19 disease and (ii) an update on the status of drug treatment and vaccine development to prevent COVID-19 and potential future related pandemics. Although the mortality rate is clearly higher than for influenza, the rate does seem to vary from country to country, possibly reflecting differences in how rapidly local health authorities respond to isolate and effectively care for the affected population. Drugs are urgently needed for both prophylaxis and the treatment of severely ill patients; however, no proven effective therapies for SARS-CoV-2 currently exist. A number of drugs that have been approved for other diseases are being tested for the treatment of COVID-19 patients, but there is an absence of data from appropriately designed clinical trials showing that these drugs, either alone or in combination, will prove effective. There is also a global urgency to develop a vaccine against COVID-19, but development and appropriate testing will take at least a year before such a vaccine will be globally available. This review summarizes the lessons learnt so far from the COVID-19 pandemic, examines the evidence regarding the drugs that are being tested for the treatment of COVID19, and describes the progress made in efforts to develop an effective vaccine.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
COVID-19 Vaccines
viruses
Pneumonia, Viral
Population
lcsh:QR1-502
Psychological intervention
Disease
Microbiology
lcsh:Microbiology
drugs
Betacoronavirus
03 medical and health sciences
0302 clinical medicine
Pandemic
medicine
Humans
030212 general & internal medicine
Intensive care medicine
education
Pandemics
Molecular Biology
education.field_of_study
SARS-CoV-2
business.industry
Viral Vaccine
Mortality rate
Outbreak
COVID-19
Viral Vaccines
Therapeutics and Prevention
vaccines
QR1-502
COVID-19 Drug Treatment
Clinical trial
030104 developmental biology
Communicable Disease Control
Minireview
Coronavirus Infections
business
Subjects
Details
- Language :
- English
- ISSN :
- 23795042
- Volume :
- 5
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- mSphere
- Accession number :
- edsair.doi.dedup.....a81aba1a827f36bd80e71ebe07a47216